MEDI0457
Showing 1 - 5 of 5
Head Neck Cancer, Human Papilloma Virus Trial in United States (MEDI0457, CELLECTRA®5P device, Durvalumab)
Completed
- Head and Neck Cancer
- Human Papilloma Virus
- MEDI0457
- +2 more
-
San Francisco, California
- +13 more
Aug 3, 2022
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA
Active, not recruiting
- Human Papillomavirus-16 Positive
- +20 more
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- Durvalumab
-
Houston, TexasM D Anderson Cancer Center
Feb 11, 2022
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC) Trial in
Recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- +2 more
- pembrolizumab
- +7 more
-
Long Beach, California
- +158 more
Jan 19, 2023
Women Receiving Standard of Care for Treatment of Pelvic Pain
Terminated
- Endometriosis
- +2 more
-
Birmingham, Alabama
- +116 more
Nov 16, 2021
